ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 105 citations in OpenAlex.
- Signaling Under Stress: Targeting the Glucocorticoid Receptor in Cancer.Cancer research · 2026Review
- Premedication with steroids in breast cancer - supportive treatment or tumour growth promotion?Magyar onkologia · 2026Review
- Exploring glucocorticoid receptor signalling in lymphangioleiomyomatosis.ERJ open research · 2026Article
- Article
- Targeting glucocorticoid receptor to enhance immunotherapy response in triple negative breast cancer.Breast cancer research : BCR · 2026Article
- Genomic Crosstalk Between Nuclear Receptors in Hormone-dependent Cancers.Endocrinology · 2025Review
- Carboplatin, gemcitabine, and mifepristone for advanced breast and recurrent/persistent epithelial ovarian cancer.Breast cancer research and treatment · 2025Article
- Genetic insights into the relationship between anti-inflammatory drug target genes and oral diseases.Inflammopharmacology · 2025Article
- The impact of glucocorticoid receptor transactivation on context-dependent cell migration dynamics.Scientific reports · 2025Article
- High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration.Breast cancer research and treatment · 2025Article
- Super-enhancer Activates Master Transcription Factor NR3C1 Expression and Promotes 5-FU Resistance in Gastric Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Steroid hormone receptors, exome sequencing and treatment responsiveness of breast cancer patient-derived xenografts originated in a South American country.Scientific reports · 2025Article
- Synthesis and Anti-Cancer Activity In Vitro of Synephrine Derivatives.Biomolecules · 2024Article
- Targeting glucocorticoid receptor signaling pathway for treatment of stress-related brain disorders.Pharmacological reports : PR · 2024Review
- Regulatory mechanisms of steroid hormone receptors on gene transcription through chromatin interaction and enhancer reprogramming.Cellular oncology (Dordrecht, Netherlands) · 2024Review
- Glucocorticoid receptors orchestrate a convergence of host and cellular stress signals in triple negative breast cancer.The Journal of steroid biochemistry and molecular biology · 2024Review
- MYC activity at enhancers drives prognostic transcriptional programs through an epigenetic switch.Nature genetics · 2024Article
- Glucocorticoid receptor: a harmonizer of cellular plasticity in breast cancer-directs the road towards therapy resistance, metastatic progression and recurrence.Cancer metastasis reviews · 2024Review
- Article
- Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.EMBO molecular medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 7 institutions in 3 countries.
Diana C WestDepartment of Medicine, The University of Chicago, Chicago, Illinois.
Masha KocherginskyDepartment of Preventive Medicine, Northwestern University, Chicago, Illinois.
Eva Y Tonsing-CarterDepartment of Medicine, The University of Chicago, Chicago, Illinois.
D Nesli DolcenDepartment of Medicine, The University of Chicago, Chicago, Illinois.
David J HosfieldBen May Department for Cancer Research, The University of Chicago, Chicago, Illinois.
Ricardo R LastraDepartment of Medicine, The University of Chicago, Chicago, Illinois.
Jason P SinnwellDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Kevin J ThompsonDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Kathleen R BowieDepartment of Medicine, The University of Chicago, Chicago, Illinois.
Ryan V HarklessDepartment of Medicine, The University of Chicago, Chicago, Illinois.
Maxwell N SkorDepartment of Medicine, The University of Chicago, Chicago, Illinois.
Charles F PierceDepartment of Medicine, The University of Chicago, Chicago, Illinois.
Sarah C StykeDepartment of Medicine, The University of Chicago, Chicago, Illinois.
Caroline R KimDepartment of Medicine, The University of Chicago, Chicago, Illinois.
Larischa de WetDepartment of Medicine, The University of Chicago, Chicago, Illinois.
Geoffrey L GreeneBen May Department for Cancer Research, The University of Chicago, Chicago, Illinois.ORCID 0000-0001-6894-8728
Judy C BougheyDepartment of Surgery, Mayo Clinic, Rochester, Minnesota.
Matthew P GoetzDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota.
Krishna R KalariDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Liewei WangDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota.
Gini F FlemingDepartment of Medicine, The University of Chicago, Chicago, Illinois.
Balázs GyörffyMTA-TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Budapest, Hungary.
Suzanne D ConzenDepartment of Medicine, The University of Chicago, Chicago, Illinois. sconzen@medicine.bsd.uchicago.edu.
University of Chicago · USMayo Clinic · USMayo Clinic in Florida · USMay Institute · USAve Maria University · USNorthwestern University · USSemmelweis University · HU
Funding
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3MVIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI CHIEN-MIN KAO · 1985 to 2026
$122.1MThe Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI Fergus Joseph Couch · 2005 to 2026
$49.9MGlucocorticoid receptor-mediated survival signaling in breast cancerR01CA089208 · NCI · UNIVERSITY OF CHICAGO · PI CONZEN, SUZANNE DANIELA · 2002 to 2016
$3.0MInvestigate the role of TPD52-AMPK pathway in tumorigenesis and cancer therapyR01CA196648 · NCI · MAYO CLINIC ROCHESTER · PI WANG, LIEWEI · 2016 to 2020
$1.7MNCI NIH HHS N01 CA015083NCI NIH HHS P30 CA014599NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA116201NCI NIH HHS R01 CA089208NCI NIH HHS R01 CA196648
Abstract
PubMed holds no abstract for this paper.
Indexed as
Gene Expression Regulation, NeoplasticTranscriptomeAnimalsAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsCell Line, TumorCell SurvivalDisease Models, AnimalDisease ProgressionDrug Resistance, NeoplasmFemaleGene Expression ProfilingHumansMicePrognosisAntineoplastic AgentsBiomarkers, TumorReceptors, EstrogenReceptors, GlucocorticoidRNA, Small Interfering
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.